Snehal Patel Buys 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 3,200 shares of the company’s stock in a transaction dated Monday, December 30th. The stock was acquired at an average cost of $11.12 per share, with a total value of $35,584.00. Following the transaction, the chief executive officer now directly owns 5,539,302 shares of the company’s stock, valued at approximately $61,597,038.24. This represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Greenwich LifeSciences Stock Up 9.7 %

Greenwich LifeSciences stock opened at $12.88 on Friday. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44. The firm has a fifty day moving average of $13.20 and a 200-day moving average of $14.20. The firm has a market capitalization of $169.37 million, a P/E ratio of -16.10 and a beta of 1.61.

Institutional Investors Weigh In On Greenwich LifeSciences

Large investors have recently made changes to their positions in the business. Rhumbline Advisers acquired a new stake in shares of Greenwich LifeSciences in the second quarter worth $117,000. Barclays PLC increased its position in shares of Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after acquiring an additional 6,538 shares in the last quarter. Garden State Investment Advisory Services LLC acquired a new stake in Greenwich LifeSciences during the 3rd quarter valued at $253,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences during the 2nd quarter valued at $264,000. Finally, State Street Corp grew its holdings in Greenwich LifeSciences by 4.4% during the 3rd quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after purchasing an additional 3,005 shares in the last quarter. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.